Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Financial Officer | July 28, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 233,421 |
Reported balance
After 2026-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 31,667 · Balance 233,421 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. F2: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan |
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 212,204 |
Reported balance
After 2026-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-29 · Sale · Disposed 21,217 · Balance 212,204 F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan
F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 4, 2024 19:50 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004231 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,397 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 1, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 15,000 | $17.90 | $268,500.00 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · nonDerivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,730 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 13,872 | $18.58 | $257,741.76 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,730 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $17.40 | $0.00 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · derivative · entry 7 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2034-01-03 F7 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 30,889 | $17.40 | $537,468.60 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,602 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,491 F4 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 18,233 | $17.40 | $317,254.20 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,491 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 28,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000929 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,724 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 19:07 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $13.07 | $0.00 |
DisclosureSEC source: 0001209191-23-024722 · doc4.xml · derivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2028-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: One-third of the shares subject to the option vested on the grant date and one-third of the shares subject to the option vested on each one year anniversary of the grant date of August 31, 2018. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 19:07 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 7,500 | $20.00 | $150,000.00 |
DisclosureSEC source: 0001209191-23-024722 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 19:07 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 7,500 | $13.07 | $98,025.00 |
DisclosureSEC source: 0001209191-23-024722 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 4,097 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · derivative · entry 14 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,097 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy · Derivative | 37,447 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · derivative · entry 13 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 37,447 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 41,544 | $18.00 | $747,792.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 8 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 4,097 | $7.77 | $31,833.69 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 7 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 37,447 | $5.80 | $217,192.60 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy · Derivative | 14,553 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · derivative · entry 12 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,447 Underlying: Common Stock · 14,553 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy · Derivative | 30,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · derivative · entry 11 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy · Derivative | 8,500 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · derivative · entry 10 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 3,242 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · derivative · entry 9 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,847 Underlying: Common Stock · 3,242 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. F3 · balance_after: The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 56,295 | $18.00 | $1,013,518.29 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 14,553 | $5.80 | $84,407.40 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 30,000 | $4.88 | $146,400.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 8,500 | $4.68 | $39,780.00 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 17:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 3,242 | $7.77 | $25,190.34 |
DisclosureSEC source: 0001209191-23-024227 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 30,911 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · derivative · entry 14 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,911 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 55,166 | $17.57 | $969,266.62 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 9 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,279 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 56,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 8 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,445 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 30,911 | $18.00 | $556,398.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 7 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,778 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 30,911 | $7.77 | $240,178.47 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · derivative · entry 13 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2028-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 12,250 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · derivative · entry 12 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,250 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $7.69 | $0.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · derivative · entry 11 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2029-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: One-third of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · derivative · entry 10 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 131,029 | $17.00 | $2,227,820.57 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,778 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 7,500 | $4.12 | $30,900.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 12,250 | $4.65 | $56,962.50 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 42,000 | $7.69 | $322,980.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:24 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 32,000 | $8.52 | $272,640.00 |
DisclosureSEC source: 0001209191-23-022398 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 04, 2023 Filed Jan 4, 2023 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 20,708 | $8.42 | $174,361.36 |
DisclosureSEC source: 0001209191-23-001343 · doc4.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,057 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 204,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-001343 · doc4.xml · derivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires 2033-01-03 F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 23,933 | $8.52 | $203,909.16 |
DisclosureSEC source: 0001209191-23-001343 · doc4.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,765 F5 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 90,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001343 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,698 F4 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 19,697 | $9.40 | $185,151.80 |
DisclosureSEC source: 0001209191-23-001343 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,031 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 20,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001343 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,728 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 1,080 shares acquired on May 20, 2022 and 1,111 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 19:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 8,835 | $4.62 | $40,817.70 |
DisclosureSEC source: 0001209191-22-001988 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,304 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-22-001988 · doc4.xml · derivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-01-03 F4 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 53,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001988 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,139 F3 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 3,097 | $4.88 | $15,113.36 |
DisclosureSEC source: 0001209191-22-001988 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,806 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. F2 · balance_after: Includes 418 shares acquired on November 19, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 17:43 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,306 | $6.50 | $14,989.00 |
DisclosureSEC source: 0001209191-21-058246 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,485 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.